First, we evaluated adverse events on the hearts of young adult mice receiving anti-CTLA-4 antibody treatment based on both levels of cardiac troponin I (TNNI3, a routine diagnostic marker for various heart disorders) as serum marker and histological analysis. Here, CTLA4 is linked to heart disorder.